PE's Diagnostic Start-Up
This article was originally published in Start Up
Less than four months after securing a broad license from Roche Molecular Systems to use PCR for clinical diagnostics, PE Corp. has hired Roche Molecular's CEO, Kathy Ordonez. PE has tasked her to build a new division within PE that will draw on technology resident in PE's Applied Biosystems Group and Celera Genomics Group, to develop, seek approval for, and market reagent and software-based standardized molecular diagnostic tests that will run on ABI's instruments.
You may also be interested in...
Applera Corp.'s new $75 million high-throughput genotyping initiative to be equally funded by its three businesses, Celera Genomics Group, Applied Biosystems Group, and Celera Diagnostics (a joint venture of Celera Genomics and Applied Bio) has provided a context for the company to begin to reveal its diagnostics strategy. New information about the structure of the joint venture also sheds more light on the acceleration of Celera Genomics' business strategy as it moves toward a collaborator-oriented drug discovery company model.
Roche Diagnostics is the best performing asset at Roche. As the troubled Swiss pharma company suffers through its worst pipeline drought in a decade, Roche Diagnostics is delivering a stellar performance. It is strong across all business segments, from laboratory systems to diabetes to molecular testing. Its challenge: to pull far enough ahead in its traditional businesses to maintain a comfortable lead. Its bigger hurdle, however, is to position itself as a leader in adoption of new genomic and proteomic diagnostic technologies, which is where the industry's future growth lies.
The latest accelerated approval withdrawals in the US are milestones for accountability in the program – most notably with the withdrawal of an antimicrobial with confirmatory studies more than a decade overdue.